Atara Biotherapeutics, Inc. (ATRA)
NASDAQ
Closed
Oct 23, 2026
Day's Range
8.5552 wk Range
3.92Overview - ATRA - Atara Biotherapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
94.05M
P/E (Trailing)
3.81
P/E (Forward)
6.13
PEG Ratio
-0.01
Price / Sales (TTM)
15.36
Price / Book
-3.86
EV / EBITDA
-8.50
Profitability
Gross Margin
69.68%
Profit Margin
-269.42%
Operating Margin
-627.46%
Return on Assets
-24.13%
Return on Equity
-84.89%
Ownership
Shares Outstanding
9.44M
Float
4.62M
Short % of Shares Outstanding
5.50%
Held by Insiders
16.79%
Held by Institutions
57.67%
Price stats
Beta
0.21
50-Day Avg
9.12
200-Day Avg
8.09
Dividends
Payout Ratio
0.00%
Analyst Consensus
3 analysts
Average price target
$ 13.67Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ATRA - Atara Biotherapeutics, Inc.
Peers - ATRA - Atara Biotherapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ATRANASDAQAtara Biotherapeutics, Inc.95.15MMarket Cap-58.65%52-week change3.82P/E (Trailing)-269.42%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - ATRA - Atara Biotherapeutics, Inc.
About
Atara Biotherapeutics, Inc. is a biotechnology company focused on allogeneic T-cell immunotherapy. Atara Biotherapeutics develops off-the-shelf cell-based therapies designed to address serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. Its current portfolio centers on…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
